Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Immunology
Immunology · The big question

Boehringer Bets Up to 407 Million Euros on Novel Autoimmune Drug

Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset

Fierce Biotech1 min readAI-assisted summary
Editorial illustration for Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
Editorial illustration

Summary

Pharmaceutical giant Boehringer Ingelheim has purchased the global rights to a new medication currently being developed by Immunitas Therapeutics. The drug is an antibody, which is a specially designed protein that can target specific parts of the immune system.

This particular antibody is intended to treat chronic inflammatory and autoimmune diseases, conditions where the immune system mistakenly attacks the body. It is described as a first-in-class treatment, meaning it is designed to work in a completely new way compared to existing medicines. To secure this promising drug, Boehringer Ingelheim has agreed to a deal worth up to 407.5 million euros.

However, that massive payout comes with strings attached. The agreement is structured using milestone payments that the pharmaceutical industry often refers to as biobucks. This means the money will only be paid out in installments if the drug hits specific clinical or commercial goals in the future. This payment structure highlights that the medication is still in its early stages of development, and its full valuation is not yet guaranteed.

Why it matters.

Autoimmune and chronic inflammatory diseases are notoriously difficult to manage, leaving many patients searching for better options. Because this new antibody from Immunitas Therapeutics is designated as a first-in-class asset, it could eventually offer a completely novel approach for people who have not found relief from currently available therapies.

From an industry perspective, this deal highlights how major pharmaceutical companies balance acquiring innovative science with financial caution. By relying heavily on milestone payments rather than a massive upfront cost, Boehringer Ingelheim protects its investment. If the drug fails during its continued development, the company is not on the hook for the full 407.5 million euros. If it succeeds, they own the global rights to a potentially valuable new therapy.

From the source

The story in numbers.

Potential deal value (biobucks)
407.5 million euros
First-in-class antibody asset
1
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Immunology

HPV and measles vaccines save the most lives per dose, study finds

Researchers recently set out to answer a crucial global health question: which vaccines save the most lives per dose? To find out, they analyzed vaccination programs for 14 preventable diseases across 117 low-income and middle-income countries. These nations are supported by Gavi, a global health alliance that helps fund and distribute vaccines. By looking at these programs, the researchers calculated an impact ratio for each disease, which simply measures how many deaths are averted for every 1,000 vaccinations given. Two vaccines stood out clearly from the rest. The vaccine against human papillomavirus, commonly known as HPV, generated the highest impact, preventing just over 11 deaths for every 1,000 vaccinations. The measles vaccine followed closely behind, averting about six deaths per 1,000 doses. For the other vaccines included in the study, the life-saving impact varied significantly based on the specific geographical region and the type of immunization program being run. However, the researchers are careful to point out some early-stage limitations. Because this is a computer modeling study, it relies on complex mathematical formulas rather than direct real-world counting. The researchers noted that there are built-in uncertainties in the data and the models. Because of these mathematical variables, the estimated impact ratios for many of the vaccines overlap, meaning it is difficult to create a perfect, rigid ranking for every single shot.

PubMed2 min read
Immunology

Unlocking a Surprising Immune Defense Against Leprosy and TB

Our immune system relies on special molecules to act as display windows, showing fragments of invading bugs to disease-fighting T cells. For years, scientists believed a specific display molecule called CD1a had a very narrow job. They thought it only presented fatty, lipid-based molecules from invaders. However, while studying the immune response to the bacteria that cause leprosy, researchers stumbled upon a surprising discovery. They found that CD1a can actually display standard protein fragments, known as peptides, effectively rewriting the rulebook on how this molecule functions. The researchers pinpointed two specific bacterial proteins, known as LppX and Ag85A, that trigger this newly discovered process. When the bacteria are broken down into small, 12-part pieces, these protein fragments bind to the CD1a molecule. Once displayed, they strongly activate CD4 T cells, which are vital immune defenders. In response, these T cells multiply and release protective, antimicrobial chemicals to help fight off the infection. To see how this plays out in humans, the scientists looked at samples from people with leprosy. They discovered that patients undergoing intense immune flare ups, known as reversal reactions, had a much higher number of these specific T cells compared to healthy donors or patients with a more severe, uncontrolled form of the disease.

bioRxiv2 min read
Immunology

Shingles Vaccine Highly Effective for Autoimmune Patients

Patients with inflammatory rheumatic diseases, such as lupus, have immune systems that mistakenly attack their own bodies. Because they often take medications that suppress their immunity to manage these conditions, they are at a much higher risk of developing shingles. Shingles, or herpes zoster, is a painful skin rash caused by the reactivation of the chickenpox virus. Fortunately, researchers have found that a modern two-dose shot called the recombinant zoster vaccine is highly effective at preventing this condition. Real-world data shows the vaccine reduces the chance of a shingles relapse by about 95 percent in these vulnerable patients. A major concern for anyone with an autoimmune condition is whether a vaccine might accidentally trigger a "flare," causing their underlying disease symptoms to worsen. Reassuringly, controlled clinical trials indicate that the short-term risk of a flare after getting the shingles vaccine is generally no different than receiving a placebo. However, researchers are still paying close attention to real-world safety reports. A broad safety analysis of 920 autoimmune patients found that 8.5 percent experienced a disease flare after vaccination, representing a threefold increase in the odds of such events being reported. Patients with systemic lupus erythematosus appear to face a notably higher risk for these post-vaccination flares. Because of this, researchers emphasize that doctors should closely monitor these specific patients in the weeks following their shots. The crucial takeaway is that the risk of a temporary flare should prompt careful observation and patient counseling, rather than causing patients to avoid the vaccine entirely.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Boehringer Bets Up to 407 Million Euros on Novel Autoimmune Drug — Daily Strand